We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+38.45%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$617M
AUM Growth
+$270M
Cap. Flow
+$176M
Cap. Flow %
28.52%
Top 10 Hldgs %
38.27%
Holding
109
New
46
Increased
22
Reduced
16
Closed
21

Top Buys

1
ZBH icon
Zimmer Biomet
ZBH
+$15.9M
2
ABT icon
Abbott
ABT
+$12.9M
3
DBVT
DBV Technologies
DBVT
+$8.68M
4
CELG
Celgene Corp
CELG
+$8.12M
5
CYNO
Cynosure, Inc. Class A
CYNO
+$7.79M

Top Sells

1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$12.1M
2
MDT icon
Medtronic
MDT
+$8.68M
3
BLUE
bluebird bio
BLUE
+$6.15M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$5.68M
5
CNMD icon
CONMED
CNMD
+$5.52M

Sector Composition

1 Healthcare 51.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARIA
76
PUT
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$1.37M 0.22%
+100,000
New +$1M
CRBP icon
77
Corbus Pharmaceuticals
CRBP
$167M
$1.36M 0.22%
6,667
-3,333
-33% -$415K
TNDM icon
78
Tandem Diabetes Care
TNDM
$1.17B
$1.15M 0.19%
15,000
– –
AVXS
79
DELISTED
AveXis, Inc. Common Stock
AVXS
$1.09M 0.18%
+26,536
New +$1.01M
IONS icon
80
Ionis Pharmaceuticals
IONS
$8.99B
$916K 0.15%
+25,000
New +$782K
NVAX icon
81
CALL
Novavax
NVAX
$1.35B
$832K 0.13%
+20,000
New +$2.58M
ALDR
82
DELISTED
Alder Biopharmaceuticals
ALDR
$524K 0.09%
+16,000
New +$487K
QTNT
83
DELISTED
Quotient Limited Ordinary Shares
QTNT
$469K 0.08%
+1,500
New +$422K
NVAX icon
84
PUT
Novavax
NVAX
$1.35B
$416K 0.07%
+10,000
New +$1.29M
AKTX
85
Akari Therapeutics
AKTX
$19.3M
$397K 0.06%
58
– –
SYRE icon
86
Spyre Therapeutics
SYRE
$8.7B
$321K 0.05%
2,000
– –
SGYP
87
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$303K 0.05%
55,000
+33,000
+150% +$154K
RCKT icon
88
CALL
Rocket Pharmaceuticals
RCKT
$376M
$196K 0.03%
+5,175
New +$163K
ASND icon
89
Ascendis Pharma A/S
ASND
$17.1B
– –
-100,000
Closed -$1.33M
GILD icon
90
Gilead Sciences
GILD
$167B
– –
-15,000
Closed -$1.25M
HRTX icon
91
Heron Therapeutics
HRTX
$89.1M
– –
-25,000
Closed -$451K
LAB icon
92
Standard BioTools
LAB
$350M
– –
-150,000
Closed -$1.35M
MDT icon
93
Medtronic
MDT
$106B
– –
-100,000
Closed -$8.68M
NBIX icon
94
Neurocrine Biosciences
NBIX
$17.2B
– –
-125,000
Closed -$5.68M
PCRX icon
95
Pacira BioSciences
PCRX
$1.01B
– –
-120,000
Closed -$4.05M
SAGE
96
CALL
DELISTED
Sage Therapeutics
SAGE
– –
-150,000
Closed -$4.52M
SPY icon
97
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$774B
– –
-100,000
Closed -$20.9M
ITCI
98
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-120,000
Closed -$4.66M
ICPT
99
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-35,000
Closed -$4.99M
ICPT
100
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-12,700
Closed -$1.81M
1 2 3
4
5

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q3 2016 Portfolio in Review

As of Q3 2016, Ghost Tree Capital held 109 positions worth $617M, up 78% from $346M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Ghost Tree Capital deployed $176M of net new capital in Q3 2016, opening 46 new positions and adding to 22 existing holdings. Its largest new stake was Zimmer Biomet: 128,750 shares worth $16.3M.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, down from 56% a quarter earlier.

On the sell side, the largest reduction was bluebird bio, an estimated $6.15M trimmed.

  • Ghost Tree Capital's largest Q3 2016 buy was Zimmer Biomet: 128,750 shares worth $16.3M.
  • Ghost Tree Capital added most to Celgene Corp in Q3 2016, an estimated $8.12M increase.
  • Ghost Tree Capital's biggest Q3 2016 reduction was bluebird bio, cutting an estimated $6.15M.
  • Ghost Tree Capital fully exited IVERIC bio, Inc. Common Stock in Q3 2016, selling an estimated $12.1M.
  • Ghost Tree Capital's ten largest holdings make up 38% of its $617M portfolio in Q3 2016.
  • Ghost Tree Capital opened 46 new positions and closed 21 in Q3 2016.
  • Ghost Tree Capital's portfolio value rose 78% quarter-over-quarter to $617M.

Based on Ghost Tree Capital's 13F filing for Q3 2016, filed 14 Nov 2016.